Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

There was HKD2 billion, HKD779 million and HKD556.9 million Southbound Trading net inflow to TRACKER FUND (02800.HK), AKESO ...

Summit Therapeutics Inc.’s SMMT share price has surged by 6.58%, which has investors questioning if this is right time to ...

MerckMRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Summit Therapeutics Inc. is currently enrolling patients in the Harmoni-7 study, a multiregional Phase III clinical trial ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

6862.HK Haidilao International Holding Ltd.